tbuckley/cabot-search huggingface dataset:
Unveiling the Impact of Hemodynamics on Endothelial Inflammation‐Mediated Hepatocellular Carcinoma Metastasis Using a Biomimetic Vascular Flow Model
Authors: Jia He, Peiyan Duan, Yi Liu, Tang Feng, Shuo Wang, Xinyi Lin, Jing Xie, Xiaoheng Liu
Journal: Advanced Healthcare Materials (2024)

Hepatocellular carcinoma (HCC) hematogenous dissemination is a leading cause of HCC-related deaths. The inflammatory facilitates this process by promoting the adhesion and invasion of tumor cells in the circulatory system. But the contribution of hemodynamics to this process remains poorly understood due to the lack of a suitable vascular flow model for investigation. This study develops a vascular flow model to examine the impact of hemodynamics on endothelial inflammation-mediated HCC metastasis. This work finds the increasing shear stress will reduce the recruitment of HCC cells by disturbing adhesion forces between endothelium and HCC cells. However, this reduction will be restored by the inflammation. When applying high FSS (4-6 dyn cm
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis
Authors: Jaleh Fallah, Haley Gittleman, Chana Weinstock, Elaine Chang, Sundeep Agrawal, Shenghui Tang, Richard Pazdur, Paul G Kluetz, Daniel L Suzman, Laleh Amiri-Kordestani
Journal: JNCI Journal of the National Cancer Institute (2024)

This pooled analysis of patient-level data from trials evaluated the clinical outcomes of patients with metastatic renal cell carcinoma with or without cytoreductive nephrectomy before a combination of immune checkpoint inhibitor and antiangiogenic therapy.
Can confocal laser endomicroscopy replace frozen section in diagnosis of brain tumors? A definite maybe
Authors: Mirna Lechpammer
Journal: Neuro-Oncology (2024)

Journal Article Can confocal laser endomicroscopy replace frozen section in diagnosis of brain tumors? A definite maybe Get access Mirna Lechpammer Mirna Lechpammer Department of Biochemistry and Molecular Pharmacology, New York University Langone Medical Center, New York, New York, USA Corresponding Author: Mirna Lechpammer, MD, PhD, Department of Biochemistry and Molecular Pharmacology, New York University Langone Medical Center, New York, NY 10016, USA (mirna.lechpammer@nyulangone.org). https://orcid.org/0000-0002-6235-6227 Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 26, Issue 5, May 2024, Pages 933–934, https://doi.org/10.1093/neuonc/noae042 Published: 15 March 2024 Article history Published: 15 March 2024 Corrected and typeset: 26 March 2024
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
Authors: Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Zafer Gülbas, Tobias Gedde-Dahl, Cristina Castilla-Llorente, Nicolaus Kröger, Mathias Eder, Alessandro Rambaldi, Francesca Bonifazi, Igor Wolfgang Blau, Matthias Stelljes, Peter Dreger, Ivan Moiseev, Hélène Schoemans, Christian Koenecke, Zinaida Peric
Journal: Blood Cancer Journal (2024)

There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing clinical use. It is currently impossible to give general recommendations regarding preference for one method over another since comparative evidence from larger data sets is lacking. To improve the evidence base, we analyzed the outcome of rATG vs. PTCy prophylaxis in adult patients with hematologic malignancies undergoing first peripheral blood alloSCT from MMUD (9/10 antigen match) between Jan 2018 and June 2021 in the database of the European Society for Blood and Marrow Transplantation (EBMT). We performed multivariate analyses using the Cox proportional-hazards regression model. We included 2123 patients in the final analyses (PTCy, n = 583; rATG, n = 1540). p values and hazard ratios (HR) presented here are multivariate outcomes. Two years after alloSCT we found a lower NRM in the PTCy group of 18% vs. 24.9% in the rATG group; p = 0.028, HR 0.74. Overall survival in the PTCy cohort was higher with 65.7% vs. 55.7% in the rATG cohort; p < 0.001, HR 0.77. Progression-free survival was also better in the PTCy patients with 59.1% vs. 48.8% when using rATG; p = 0.001, 0.78. The incidences of chronic GVHD and acute GVHD were not significantly different between the groups. We found significantly lower NRM as well as higher survival in recipients of peripheral blood alloSCTs from MMUD receiving PTCy as compared to rATG. The results of the current analysis suggest an added value of PTCy as GVHD prophylaxis in MMUD alloSCT.
MRI-based synthetic CT: a new method for structural damage assessment in the spine in patients with axial spondyloarthritis – a comparison with low-dose CT and radiography
Authors: Simone Tromborg Willesen, Anna EF Hadsbjerg, Jakob Møllenbach Møller, Nora Vladimirova, Bimal M K Vora, Sengül Seven, Susanne Juhl Pedersen, Mikkel Østergaard
Journal: Annals of the Rheumatic Diseases (2024)

To investigate the ability of MRI-based synthetic CT (sCT), low-dose CT (ldCT) and radiography to detect spinal new bone formation (NBF) in patients with axial spondyloarthritis (axSpA).
RORγt up-regulates RAG gene expression in DP thymocytes to expand the <i>Tcra</i> repertoire
Authors: Abani Kanta Naik, Danielle J. Dauphars, Elizabeth Corbett, Lunden Simpson, David G. Schatz, Michael S. Krangel
Journal: Science Immunology (2024)

Recombination activating gene (RAG) expression increases as thymocytes transition from the CD4
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Authors: Wei Wang, Najah Albadari, Yi Du, Josef F. Fowler, Hannah T. Sang, Wa Xian, Frank McKeon, Wei Li, Jia Zhou, Ruiwen Zhang
Journal: Pharmacological Reviews (2024)

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the development of cancer therapy. MDM29s activities extend from carcinogenesis to immunity, to the response to various cancer therapies. Since the report of the first MDM2 inhibitor more than 30 years ago, various approaches to inhibit MDM2 have been attempted, with hundreds of small molecule inhibitors evaluated in preclinical studies and numerous molecules tested in clinical trials. Although many MDM2 inhibitors and degraders have been evaluated in clinical trials, there is currently no FDA-approved MDM2 inhibitor on the market. Nevertheless, there are several current clinical trials of promising agents that may overcome the past failures, including agents granted FDA orphan drug or fast-track status. We herein summarize the research efforts to discover and develop MDM2 inhibitors, focusing on those that induce MDM2 degradation and exert anticancer activity, regardless of the p53 status of the cancer. We also describe how preclinical and clinical investigations have moved towards combining MDM2 inhibitors with other agents, including immune checkpoint inhibitors. Finally, we discuss the current challenges and future directions to accelerate the clinical application of MDM2 inhibitors. In conclusion, targeting MDM2 remains a promising treatment approach, and targeting MDM2 for protein degradation represents a novel strategy to downregulate MDM2 without the side effects of the existing agents blocking p53-MDM2 binding. Additional preclinical and clinical investigations are needed to finally realize the full potential of MDM2 inhibition in treating cancer and other chronic diseases where MDM2 has been implicated. <b>Significance Statement</b> Overexpression/amplification of the MDM2 oncogene has been detected in various human cancers and is associated with disease progression, treatment resistance, and poor patient outcomes. Herein, we review the previous, current and emerging MDM2-targeted therapies and summarize the preclinical and clinical studies combining MDM2 inhibitors with chemotherapy and immunotherapy regimens. The findings of these contemporary studies may lead to safer and more effective treatments for patients with cancers overexpressing MDM2.
Multidisciplinary combined treatment based on bariatric surgery for metabolic syndrome: a review article
Authors: Jiaji Xie, Yong Wang
Journal: International Journal of Surgery (2024)

As a chronic, multifactorial disease, obesity is associated with a global social and economic burden. This condition significantly affects normal daily life and healthy social interactions, and shortens the life expectancy of patients. Compared with traditional weight-loss methods, the emergence of bariatric surgery has effectively improved the management of obesity. Further, bariatric surgery can also inhibit the progression of multiple metabolic diseases. Despite its potential advantages, bariatric surgery cannot completely eliminate the possibility of weight regain and inadequate weight loss following the procedure. For super-obese patients, bariatric surgery still remains a surgical risk. In addition, the psychological problems and poor eating habits of obese patients also affect the weight loss effect and daily life. Thus, various adjuvant therapies involving multiple disciplines have attracted people’s attention. Recently, it has been recognized that the combination of multiple interventions based on bariatric surgery is more advantageous than a single intervention in alleviating the complex and diverse metabolic diseases associated with obesity. The combined therapy considerably enhances the long-term efficacy of bariatric surgery and plays a positive role in the mental health and social lives of patients. In this article, we review this multidisciplinary combination therapy to enhance the current understanding of the treatment of obesity.
Dynamic insights into infection risk over time in two-stage implant-based breast reconstruction: a retrospective cohort study
Authors: Jeong Hyun Ha, Seoin Ahn, Hong-Kyu Kim, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Ki Yong Hong, Hak Chang, Gordon K. Lee, Jinwook Choi, Ung Sik Jin
Journal: International Journal of Surgery (2024)

Background Infections following postmastectomy implant-based breast reconstruction (IBR) can compromise surgical outcomes and lead to significant morbidity. This study aimed to discern the timing of infections in two-stage IBR and associated risk factors. Method A review of electronic health records was conducted on 1,096 breasts in 1,058 patients undergoing two-stage IBR at ** National University Hospital (2015-2020). Infections following the first-stage tissue expander (TE) insertion and second-stage TE exchange were analyzed separately, considering associated risk factors. Results Over a median follow-up of 53.5 months, infections occurred in 2.9% (32/1096) after the first stage and 4.1% (44/1070) after the second stage. Infections following the first-stage procedure exhibited a bimodal distribution across time, while those after the second-stage procedure showed a unimodal pattern. When analyzing risk factors for infection after the first-stage procedure, axillary lymph node dissection (ALND) was associated with early (≤7 weeks) infection, while both ALND and obesity were independent predictors of late (&gt;7 weeks) infection. For infections following the second-stage procedure, obesity, postmastectomy radiotherapy, a history of expander infection, ALND, and the use of textured implants were identified as independent risk factors. Postmastectomy radiotherapy was related to non-salvaged outcomes after infection following both stages. Conclusion Infections following first and second-stage IBR exhibit distinct timelines reflecting different pathophysiology. Understanding these timelines and associated risk factors will inform patient selection for IBR and aid in tailored postoperative surveillance planning. These findings contribute to refining patient suitability for IBR and optimizing personalized postoperative care strategies.
Indocyanine green fluorescence applied to gynecologic oncology: beyond sentinel lymph node
Authors: Matteo Loverro, Nicolò Bizzarri, Filippo M. Capomacchia, Rafał Watrowski, Denis Querleu, Alessandro Gioè, Angelica Naldini, Francesco Santullo, Nazario Foschi, Anna Fagotti, Giovanni Scambia, Francesco Fanfani
Journal: International Journal of Surgery (2024)

Indocyanine green (ICG), a well-known molecule employed in medicine for over five decades, has emerged as a versatile dye widely embraced across various surgical disciplines. In gynecologic oncology, its prevalent use revolves around the detection of sentinel lymph nodes. However, the true potential of ICG extends beyond this singular application, owing to its pragmatic utility, cost-effectiveness, and safety profile. Furthermore, ICG has been introduced in the theranostic landscape, marking a significant juncture in the evolution of its clinical utility. This narrative review aims to describe the expanding horizons of ICG fluorescence in gynecologic oncology, beyond the sentinel lymph node biopsy. The manifold applications reported within this manuscript include: 1) lymphography; 2) angiography; 3) nerve visualization; 4) ICG-driven resections; and 5) theranostic. The extensive exploration across these numerous applications, some of which are still in the preclinical phase, serves as a hypothesis generator, aiming to stimulate the development of clinical studies capable of expanding the use of this drug in our field, enhancing the care of gynecological cancer patients.
Fermentation practices select for thermostable endolysins in phages
Authors: Frank Oechslin, Xiaojun Zhu, Carlee Morency, Vincent Somerville, Rong Shi, Sylvain Moineau
Journal: Molecular Biology and Evolution (2024)

Abstract Endolysins are produced by (bacterio)phages and play a crucial role in degrading the bacterial cell wall and the subsequent release of new phage progeny. These lytic enzymes exhibit a remarkable diversity, often occurring in a multimodular form that combines different catalytic and cell wall-binding domains, even in phages infecting the same species. Yet, our current understanding lacks insight into how environmental factors and ecological niches may have influenced the evolution of these enzymes. In this study, we focused on phages infecting Streptococcus thermophilus, as this bacterial species has a well-defined and narrow ecological niche, namely, dairy fermentation. Among the endolysins found in phages targeting this species, we observed limited diversity, with a singular structural type dominating in most of identified S. thermophilus phages. Within this prevailing endolysin type, we discovered a novel and highly conserved calcium-binding motif. This motif proved to be crucial for the stability and activity of the enzyme at elevated temperatures. Ultimately, we demonstrated its positive selection within the host's environmental conditions, particularly under the temperature profiles encountered in the production of yogurt, mozzarella, and hard cheeses that rely on S. thermophilus.
Single Dual-specific Anti-PD-L1/TGF-β Antibody Synergizes with Chemotherapy as Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma: a Preclinical Experimental Study
Authors: Haoxiang Zhang, Jiaoshun Chen, Jianwei Bai, Jing Zhang, Shaoyi Huang, Liang Zeng, Pengfei Zhou, Qiang Shen, Tao Yin
Journal: International Journal of Surgery (2024)

Aims: Chemotherapy resistance is an important cause of neoadjuvant therapy failure in pancreatic ductal adenocarcinoma (PDAC). BiTP (anti-PD-L1/TGF-β bispecific antibody) is a single antibody that can simultaneously and dually target transforming growth factor-beta (TGF-β) and programmed cell death ligand 1 (PD-L1). We attempted in this study to investigate the efficacy of BiTP in combination with first-line chemotherapy in PDAC. Methods: Preclinical assessments of BiTP plus gemcitabine and nab-paclitaxel were completed through a resectable KPC mouse model (C57BL/6J). Spectral flow cytometry, tissue section staining, enzyme-linked immunosorbent assays, Counting Kit-8, transwell, and Western blot assays were used to investigate the synergistic effects. Results: BiTP combinatorial chemotherapy in neoadjuvant settings significantly downstaged PDAC tumors, enhanced survival, and had a higher resectability for mice with PDAC. BiTP was high affinity binding to targets and reverse chemotherapy resistance of PDAC cells. The combination overcame immune evasion through reprogramming tumor microenvironment via increasing penetration and function of T cells, natural killer cells, and dendritic cells and decreasing the function of immunosuppression-related cells as regulatory T cells, M2 macrophages, myeloid-derived suppressor cells, and cancer-associated fibroblasts. Conclusion: Our results suggest that the BiTP combinatorial chemotherapy is a promising neoadjuvant therapy for PDAC.
AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension
Authors: Richard K. Sterling, Sumeet K. Asrani, Deborah Levine, Andres Duarte-Rojo, Keyur Patel, Maria Isabel Fiel, Daniel H. Leung, Bachir Taouli, Mouaz Alsawas, M. Hassan Murad, Jonathan A. Dranoff, Tamar H. Taddei, Don C. Rockey
Journal: Hepatology (2024)

Sterling, Richard K.; Asrani, Sumeet K.; Levine, Deborah; Duarte-Rojo, Andres; Patel, Keyur; Fiel, Maria Isabel; Leung, Daniel H.; Taouli, Bachir; Alsawas, Mouaz; Murad, M. Hassan; Dranoff, Jonathan A.; Taddei, Tamar H.; Rockey, Don C. Author Information
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Authors: Keyur Patel, Sumeet K. Asrani, Maria Isabel Fiel, Deborah Levine, Daniel H. Leung, Andres Duarte-Rojo, Jonathan A. Dranoff, Tarek Nayfeh, Bashar Hasan, Tamar H. Taddei, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Muayad Alzuabi, Jingyi Ding, Nigar Sofiyeva, M. Hassan Murad, Mouaz Alsawas, Don C. Rockey, Richard K. Sterling
Journal: Hepatology (2024)

Background and Aims: Blood-based biomarkers have been proposed as an alternative to liver biopsy for non-invasive liver disease assessment (NILDA) in chronic liver disease (CLD). Our aims for this systematic review were to evaluate the diagnostic utility of selected blood-based tests either alone, or in combination, for identifying significant fibrosis (F2-4), advanced fibrosis (F3-4) and cirrhosis (F4), as compared to biopsy in CLD. Approach and Results: We included a comprehensive search of databases including Ovid MEDLINE(R), EMBASE, Cochrane Database, and Scopus through to April 2022. Two independent reviewers selected 286 studies with 103,162 patients. The most frequently identified studies included the simple aminotransferase-to-platelet ratio index (APRI) and fibrosis (FIB)-4 markers (with low-to-moderate risk of bias) in hepatitis B virus (HBV) and C virus (HCV), HIV-HCV/HBV co-infection, and nonalcoholic fatty liver disease (NAFLD). Positive (LR+) and negative (LR) likelihood ratios across direct and indirect biomarker tests for HCV and HBV for F2-4, F3-4, or F4 were 1.66-6.25 and 0.23-0.80, 1.89-5.24 and 0.12-0.64, and 1.32-7.15 and 0.15-0.86 respectively; LR+ and LR for NAFLD F2-4, F3-4 and F4 were 2-65-3.37 and 0.37-0.39, 2.25-6.76 and 0.07-0.87, and 3.90 and 0.15 respectively. Overall, proportional odds ratio indicated FIB-4 &lt;1.45 was better than APRI &lt;0.5 for F2-4. FIB-4 &gt;3.25 was also better than APRI &gt;1.5 for F3-4 and F4. There was limited data for combined tests. Conclusions: Blood-based biomarkers are associated with small-to-moderate change in pre-test probability for diagnosing F2-4, F3-4, and F4 in viral hepatitis, HIV-HCV co-infection, and NAFLD, with limited comparative or combination studies for other CLD.
A commentary on ‘Risk factors for postoperative delirium: an umbrella review of systematic reviews’
Authors: Wenjuan Feng, Zhuyun Chen, Min Zhang, Wenmin Chen
Journal: International Journal of Surgery (2024)

Department of Cardiac Surgery, Yan'an Hospital of Kunming City, Kunming, People's Republic of China Wenjuan Feng and Zhuyun Chen equally contributed to the study. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Yan'an Hospital of Kunming City, Kunming, People's Republic of China. E-mail: [email protected] (M. Zhang). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
A commentary on ‘Metal ureteral stents for ureteral stricture: 2 years of experience with 246 cases’
Authors: Xinfei Li, Kunlin Yang, Xuesong Li
Journal: International Journal of Surgery (2024)

Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, No. 8 Xishiku Street, Xicheng District, Beijing 100034, People's Republic of China. Tel.: +861 083 575 101; fax: +861 066 551 726. E-mail: [email protected] (X. Li). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0/
Reply to ‘Commentary on: Mapping the landscape of immunonutrition and cancer research: a comprehensive bibliometric analysis on behalf of NutriOnc Research Group (Int J Surg 2023, Epub ahead of print)’
Authors: Francesca De Felice, Carlo G. Cattaneo, Luigi Marano
Journal: International Journal of Surgery (2024)

De Felice, Francesca MD, PhD; Cattaneo, Carlo G. MD; Marano, Luigi MD, PhD Author Information
Loss-of-function variants in <i>GLMN</i> are associated with generalized skin hyperpigmentation with or without glomuvenous malformation
Authors: Xingyuan Jiang, Chao Yang, Zhaoyang Wang, Lina Liang, Zhuoqing Gong, Shimiao Huang, Zigang Xu, Bin Zhang, Xiaoping Pei, Liangqi Cai, Huijun Wang, Zhimiao Lin
Journal: British Journal of Dermatology (2024)

Inherited hyperpigmented skin disorders comprise a group of entities with considerable clinical and genetic heterogenicity. The genetic basis of a majority of these disorders remains to be elucidated.
Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3′-Kinase/AKT Signaling
Authors: Yu-Tzu Tai, Klaus Podar, Laurence Catley, Yu-Hua Tseng, Masaharu Akiyama, Reshma Shringarpure, Renate Burger, Teru Hideshima, Dharminder Chauhan, Nicholas Mitsiades, Paul Richardson, Nikhil C. Munshi, C. Ronald Kahn, Constantine Mitsiades, Kenneth C. Anderson
Journal: Cancer Research (2024)

There are concerns about the reliability of certain data arising from errors